Physician profile
Cristobal E Cortes
NPI 1356351498
$1,163.65
in general payments reported to CMS, 2019-2025
11 companies · $146 in 2025
The $146 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87.09 · 2020: $144 · 2021: $265 · 2022: $43.42 · 2023: $79.64 · 2024: $399 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $624.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $624.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $388.21 | 2019-2024 | Airsupra |
| Abbott Laboratories | $169.22 | 2023-2024 | Mitraclip, Freestyle Libre 2 |
| Amgen INC. | $146.03 | 2025 | Repatha, Otezla |
| Abbvie INC. | $128.17 | 2022-2024 | |
| Kaleo, INC. | $119.03 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $81.52 | 2020-2021 | |
| Abiomed | $60.42 | 2023 | Impella |
| Philips North America LLC | $21.39 | 2022 | |
| Boston Scientific Corporation | $17.92 | 2019 | |
| Lilly USA, LLC | $16.90 | 2024 | Zepbound, Mounjaro |
| Sunovion Pharmaceuticals INC. | $14.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cristobal Cortes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.